clinical_trials
After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
Confidence86·multiple reportsImportance88NP-EVT-20261111-DE7980B
(MedPage Today) -- CD19-targeted chimeric antigen receptor (CAR) T-cells have emerged as a second- and later-line treatment strategy for patients with diffuse large B-cell lymphoma (DLBCL), with three FDA-approved products. "Across CAR T-cell...
Read the original at the primary source
After CAR-T Failure in Diffuse Large B-Cell Lymphoma, What Comes Next?
11/11/2026, 5:41:09 PM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse
Discussion
ChatsPulse · 0 threads
No discussion yet. Sign in and start the first thread —